Managed care executives involved with Medicare Advantage products should consider the impact of product design and cost sharing on elderly consumers, according to the findings of a recent poll.
Managed care executives involved with Medicare Advantage products should consider the impact of product design and cost sharing on elderly consumers, according to the findings of a recent poll.
The poll of more than 500 seniors, conducted by the Blue Cross Blue Shield of Massachusetts Foundation and Harvard T.H. Chan School of Public Health, found that more than one quarter of seniors aged 65 years and older are dissatisfied with their healthcare costs, and 23% say it has gotten harder to pay for healthcare over the past five years. Both concerns are higher among seniors who report poor health or a disability.
“The cost of healthcare is becoming an increasing challenge for consumers of all ages,” says Audrey Shelto, president, Blue Cross Blue Shield of Massachusetts Foundation. “Those with lower incomes or who have poor health and require more healthcare services are particularly impacted by the high out-of-pocket costs."
Related:CMS' rewards programs can impact Medicare Advantage organization's bottom lines
Some seniors in Massachusetts, particularly those with lower incomes or in poor health, do not have adequate health insurance coverage, Shelto explains.
“This is leading some to deplete their savings on medical bills while others find it difficult to afford basic necessities. And others are taking steps which could adversely impact their health such as skipping a dose of their medication or not filling a prescription,” she says.
Other findings include:
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More